EngineeredBacteriophagesforAntimicrobialTherapy

Why It Matters

Antibiotic resistance is a global health crisis, projected to cause 10 million deaths annually by 2050 and cost the global economy $100 trillion if unchecked. Engineered phage therapy could provide a crucial new weapon against these superbugs, saving countless lives and reducing healthcare costs. Patients with untreatable infections would experience life-saving treatments; biotech companies developing phage therapies would win, while traditional antibiotic manufacturers might face pressure to innovate or decline. Key barriers include regulatory pathways for living therapeutics, overcoming bacterial resistance to phages, and ensuring safe and effective delivery to infection sites. Limited clinical applications could be seen in 3-7 years, with broader use in 10-15 years. The US (NIH, DARPA), Belgium (Queen Astrid Military Hospital), and France are leaders in phage therapy research and clinical application. An underappreciated consequence is the shift from broad-spectrum treatments to highly personalized infection management, requiring rapid diagnostic capabilities to identify specific bacterial strains for targeted phage cocktails.